Expert Pitch
Mercy Medical Center

Expert on Gastrointestinal Symptoms on COVID-19 Patients

26-May-2020 8:55 AM EDT, by Mercy Medical Center contact patient services

Expert and researcher available to comment on the first prospective case-control study of GI symptoms in COVID-19 patients.

The study shows digestive issues might be an early symptom for people who have come down with the coronavirus.

It found a high prevalence of GI symptoms (74%) in COVID-19 patients, with the most common GI symptoms being anorexia (53%) and diarrhea (50%). However, GI symptoms were also prevalent (53%) in COVID-19 negative patients, and multivariable analysis showed that GI symptoms were not associated with an increased likelihood of testing positive for COVID-19. 

Because these individuals don't necessarily have respiratory symptoms, they may not seek help as quickly thinking it's not the coronavirus.

“It's very common to have upper gastrointestinal symptoms, like loss of appetite. In three out of four, you will see loss of appetite, but nausea is seen in one in four. Same thing with diarrhea. It is uncommon, but one in four can have diarrhea,” according to Dr. Thuluvath.

If you are having these symptoms, contact your doctor so he or she can advise you on how to proceed.

The virus can appear in stool, which is just one more reason to practice diligent hand washing.

 




Filters close

Showing results

110 of 2539
Released: 13-Jul-2020 4:05 PM EDT
OADN & AACN Secure No-Cost Access to COVID-19 Screening Solution Until Vaccines Become Widely Available
Organization for Associate Degree Nursing (OADN)

OADN & AACN Secure No-Cost Access to COVID-19 Screening Solution Until Vaccines Become Widely Available

Newswise: Study suggests lymphoma drug acalabrutinib might offer a potential therapeutic approach for severe COVID-19 infection
Released: 13-Jul-2020 3:45 PM EDT
Study suggests lymphoma drug acalabrutinib might offer a potential therapeutic approach for severe COVID-19 infection
Hackensack Meridian Health

The mechanisms of action of acalabrutinib led to the hypothesis it might be effective in reducing the massive inflammatory response seen severe forms of COVID19. Indeed, it did provide clinical benefit in a small group of patients by reducing their inflammatory parameters and improving their oxygenation.

Newswise: National Virtual Biotechnology Laboratory Unites DOE Labs Against COVID-19
Released: 13-Jul-2020 3:40 PM EDT
National Virtual Biotechnology Laboratory Unites DOE Labs Against COVID-19
Department of Energy, Office of Science

To focus its efforts against the COVID-19 pandemic, DOE is bringing the national laboratories together into the National Virtual Biotechnology Laboratory.

Newswise: Key Insights from Swedish Casino that Remained Open During COVID-19
Released: 13-Jul-2020 3:40 PM EDT
Key Insights from Swedish Casino that Remained Open During COVID-19
University of Nevada, Las Vegas (UNLV)

As casinos in Las Vegas enter the second month of reopening since the COVID-19 pandemic took hold, UNLV gaming researchers say they can draw upon insights from industry collaborators in Sweden, a country that took a more open approach to the crisis compared to other governments.

Released: 13-Jul-2020 3:05 PM EDT
Asymptomatic Transmission and Reinfection of COVID: Live Event for July 16, 2PM EDT
Newswise

Emerging data shows more risk of asymptomatic transmission and reinfection with COVID than previously thought. Experts will discuss these findings and what are the implications for managing the pandemic. Media are invited to attend and ask questions.

Released: 13-Jul-2020 2:40 PM EDT
Engineered llama antibodies neutralize COVID-19 virus
Rosalind Franklin Institute

Antibodies derived from llamas have been shown to neutralise the SARS-CoV-2 virus in lab tests, UK researchers announced today.

Released: 13-Jul-2020 1:25 PM EDT
1 in 3 young adults may face severe COVID-19
University of California, San Francisco (UCSF)

As the number of young adults infected with the coronavirus surges throughout the nation, a new study by researchers at UCSF Benioff Children's Hospitals indicates that youth may not shield people from serious disease.

Released: 13-Jul-2020 12:25 PM EDT
Scientists discover key element of strong antibody response to COVID-19
Scripps Research Institute

A team led by scientists at Scripps Research has discovered a common molecular feature found in many of the human antibodies that neutralize SARS-CoV-2, the coronavirus that causes COVID-19.

Released: 13-Jul-2020 11:15 AM EDT
UTHealth joins study of blood pressure medication’s effect on improving COVID-19 outcomes
University of Texas Health Science Center at Houston

An interventional therapy aimed at improving survival chances and reducing the need for critical care treatment due to COVID-19 is being investigated by physicians at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is underway at Memorial Hermann and Harris Health System’s Lyndon B. Johnson Hospital.


Showing results

110 of 2539

close
2.39345